Skip to content

Effects of individualized antihypertensive information on the medication use in hypertensive patients: An exploratory randomized controlled trial.

Effects of individualized antihypertensive information on the medication use in hypertensive patients: An exploratory randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004169
Enrollment
Unknown
Registered
2014-01-20
Start date
2014-02-17
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

1:Individualized medical information
2:only get life style education and usual medical care

Sponsors

Division of Epidemiology, JC School of Public Health and Primary Care, the Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients with primary hypertension; (2) Age range: 35-65 years old; (3) BP lower than 160/100mmHg at diagnosis, or systolic blood pressure lower than 145mmHg for patients already on antihypertensive medications measured in clinic at recruitment; (4) Patients have at least graduated from primary school; (5) No deafness, blindness, or dementia, have no difficulty in understanding the antihypertensive information and information in the questionnaire; (6) Residents in Shenzhen, patients have no plan to move to other cities or countries in the following 6 months; (7) Informed consents have been signed.

Exclusion criteria

Exclusion criteria: (1) Patients with hypertensive emergencies and urgencies, which are judged by physicians in the primary care centers; (2) Patients with drug-induced hypertension, drugs include sympathomimetic agents, non-steroidal anti-inflammatory drugs (NSAIDs) and cycloxoygenase 2 (COX-2) inhibitors, corticosteroids, central nervous system (CNS) stimulants, estrogens and progesterone, dietary supplements, serotonin-norepinephrine reuptake inhibitors (SNRIs), immunosuppressants; (3) Patients with histories of coronary heart diseases, cerebrovascular diseases, chronic heart failure, chronic renal diseases, or diabetes mellitus, etc. (4) Patients risk of cardiovascular diseases over 20% in the future ten years; (5) Patients who did not get total cholesterol (TC) measured within 2 years before the study, or those whose TC values cannot be found in the medical record; (6) Women in pregnancy or lactation; (7) Patients possibly with low compliance to follow-up.

Design outcomes

Primary

MeasureTime frame
Treatment Rate;Rate of good adherenc;

Countries

China

Contacts

Public ContactJin-Ling Tang

the Chinese University of Hong Kong

jltang@cuhk.edu.hk+852 2252 8779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026